OBJECTIVES: An association of a single nucleotide polymorphism (SNP) of the KLK2 gene (rs198977; c.748C>T; R250W) with risk for developing prostate cancer has been observed. We evaluated the role of R250W SNP for prognosis in prostate cancer. METHODS: The c.748C>T SNP was genotyped from blood DNA of 182 patients after completing initial cancer treatments. For evaluating prognosis of genotype groups, associations were performed with Gleason score (GS) and biochemical recurrence free survival (bRFS) in patients demonstrating PSA-recurrence after initial cancer therapy. RESULTS: Overall distribution of the CC, CT and TT genotypes for the SNP was 48%, 44% and 8%, respectively. The distribution of high (8-10), moderate (5-7) and low (2-4) GS among the genotype groups was 17%, 74% and 9% for CC group compared to 25%, 74% and 1% for the CT/TT (P=0.04). Median bRFS time for CT/TT group was 36.5 months compared to 44.5 months for the CC group (P=0.16), while genotype groups combined with morphology revealed significantly different bRFS (P=0.004). CONCLUSIONS: This exploratory analysis in prostate cancer patients revealed the W allele of the KLK2 R250W SNP to be less likely associated with low GS morphology. Further studies will be needed to confirm this observation in larger cohorts.
OBJECTIVES: An association of a single nucleotide polymorphism (SNP) of the KLK2 gene (rs198977; c.748C>T; R250W) with risk for developing prostate cancer has been observed. We evaluated the role of R250W SNP for prognosis in prostate cancer. METHODS: The c.748C>T SNP was genotyped from blood DNA of 182 patients after completing initial cancer treatments. For evaluating prognosis of genotype groups, associations were performed with Gleason score (GS) and biochemical recurrence free survival (bRFS) in patients demonstrating PSA-recurrence after initial cancer therapy. RESULTS: Overall distribution of the CC, CT and TT genotypes for the SNP was 48%, 44% and 8%, respectively. The distribution of high (8-10), moderate (5-7) and low (2-4) GS among the genotype groups was 17%, 74% and 9% for CC group compared to 25%, 74% and 1% for the CT/TT (P=0.04). Median bRFS time for CT/TT group was 36.5 months compared to 44.5 months for the CC group (P=0.16), while genotype groups combined with morphology revealed significantly different bRFS (P=0.004). CONCLUSIONS: This exploratory analysis in prostate cancerpatients revealed the W allele of the KLK2 R250W SNP to be less likely associated with low GS morphology. Further studies will be needed to confirm this observation in larger cohorts.
Authors: Daniel P Petrylak; Donna Pauler Ankerst; Caroline S Jiang; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford Journal: J Natl Cancer Inst Date: 2006-04-19 Impact factor: 13.506
Authors: A W Partin; M W Kattan; E N Subong; P C Walsh; K J Wojno; J E Oesterling; P T Scardino; J D Pearson Journal: JAMA Date: 1997-05-14 Impact factor: 56.272
Authors: John Concato; Carolyn K Wells; Ralph I Horwitz; David Penson; Graeme Fincke; Dan R Berlowitz; Gregory Froehlich; Dawna Blake; Martyn A Vickers; Gerald A Gehr; Nabil H Raheb; Gail Sullivan; Peter Peduzzi Journal: Arch Intern Med Date: 2006-01-09
Authors: Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Sara S Strom; Yun Gu; Hui Zhang; Patricia Troncoso; Richard J Babaian; Curtis A Pettaway; Sanjay Shete; Margaret R Spitz; Christopher J Logothetis Journal: Prostate Date: 2004-09-01 Impact factor: 4.104
Authors: Alexander Haese; Markus Graefen; Thomas Steuber; Charlotte Becker; Joachim Noldus; Andreas Erbersdobler; Edith Huland; Hartwig Huland; Hans Lilja Journal: J Urol Date: 2003-12 Impact factor: 7.450
Authors: Atsuko Shibata; Maria Isabel Garcia; Iona Cheng; Thomas A Stamey; John E McNeal; James D Brooks; Stavonnie Henderson; Cheryl E Yemoto; Donna M Peehl Journal: Prostate Date: 2002-09-01 Impact factor: 4.104
Authors: Robert K Nam; William W Zhang; John Trachtenberg; Eleftherios Diamandis; Ants Toi; Marjan Emami; Minnie Ho; Joan Sweet; Andrew Evans; Michael A S Jewett; Steven A Narod Journal: J Clin Oncol Date: 2003-06-15 Impact factor: 44.544